| Management target | Revenue 10.0% H2 FY27 |
|---|
| Revenue growth | 51% YoY growth driven primarily by JB Chemicals acquisition consolidation. |
|---|---|
| Margins | EBITDA margin at 33.5%; improving sequential JB margins from cost synergies. |
| Demand visibility | Strong domestic and Brazil demand; semi-glutide franchise market share remains high. |
| Management confidence | Balanced; optimistic on cost synergies but realistic about integration-led supply disruptions. |
Growth
Consolidated revenue ₹4,979 Cr up 51%; Brazil (+38%) and US (+24%) offset German decline.
Outlook
Management expects double-digit growth for the JB business in H2 FY27.
Risks
Integration challenges caused flat JB business and international supply postponements; German revenue fell 7%.
Earnings Call Transcript filed with NSE, NSE: TORNTPHARM. Summary written with AI assistance from the document.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,557.00
- Market cap
- ₹1,73,334 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 81.6×Sector 46.1×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.22%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Debt & Borrowing
Torrent Pharmaceuticals filed its security cover certificate as on 30-Sep-26 for listed NCDs, showing 141% market-value cover. Secured debt covered by the certificate stands at Rs 11,578.42 Crore.
Torrent Pharmaceuticals Q2 FY27 Results: Net Profit ₹534 Cr, Down 9.6% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,979 Cr (+50.8% YoY) and net profit of ₹534 Cr (-9.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹534 Cr · -9.6% YoY
Torrent Pharmaceuticals Management Change
Torrent Pharmaceuticals' Executive Director, Amal Kelshikar, has resigned from his position effective October 16, 2026.
Torrent Pharmaceuticals Credit Rating
India Ratings affirmed Torrent Pharmaceuticals' existing credit ratings and revised the outlook to positive. The company's commercial paper rating was also affirmed and assigned.
Torrent Pharmaceuticals Board Meeting Date
Torrent Pharmaceuticals will hold a board meeting on 23-Oct-26 to consider standalone audited and consolidated unaudited financial results for the quarter and half-year ended 30-Sep-26.
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals confirmed Chintan M. Trivedi as Company Secretary and Compliance Officer. KFin Technologies Limited remains the company's Registrar and Share Transfer Agent.